Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Globulins, specifically immune globulins (such as hepatitis B immune globulin, HBIG), are scientifically validated for use in the prevention and management of hepatitis, particularly hepatitis B. Immune globulins are purified antibodies derived from human plasma donors with high titers of anti-hepatitis B surface antibody. The primary clinical use is as post-exposure prophylaxis for individuals who have been exposed to hepatitis B virus (HBV) through percutaneous or mucosal exposure (such as needlestick injuries or newborns born to HBV-infected mothers). The administration of HBIG provides passive immunity by supplying specific antibodies that can neutralize the virus and prevent infection or reduce the severity of disease.

The efficacy of HBIG is well-documented in medical literature and endorsed by major health organizations including the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO). Its use, in conjunction with the hepatitis B vaccine, has significantly reduced the incidence of perinatal and occupational HBV transmission. However, globulins are not used as a curative treatment for established chronic hepatitis B infection; rather, they are employed for short-term protection in at-risk individuals. There is less evidence for the use of non-specific globulins or immune globulins in other types of hepatitis (such as hepatitis C or autoimmune hepatitis).

In summary, the use of globulins, specifically immune globulins, in hepatitis B prophylaxis is strongly supported by scientific evidence, though their role is mainly preventive rather than therapeutic for chronic disease.

More about Globulins
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Globulins

Products containing Globulins